Heart, Lung and Circulation
Review| Volume 24, ISSUE 6, P536-543, June 2015

Northern Territory Perspectives on Heart Failure with Comorbidities – Understanding Trial Validity and Exploring Collaborative Opportunities to Broaden the Evidence Base

Published:December 23, 2014DOI:
      Congestive Heart Failure (CHF) is an ambulatory care sensitive condition, associated with significant morbidity and mortality, rarely with cure. Outpatient based pharmacological management represents the main and most important aspect of care, and is usually lifelong. This narrative styled opinion review looks at the pharmacological agents recommended in the guidelines in context of the Northern Territory (NT) of Australia. We explore the concept of validity, a term used to describe the basis of standardising a particular trial or study and the population to which it is applicable. We aim to highlight the problems of the current guidelines based approach. We also present alternatives that could utilise the core principles from major trials, while incorporating regional considerations, which could benefit clients living in the NT and remote Australia.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Heart, Lung and Circulation
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Iyngkaran P.
        • Majoni V.
        • Nadarajan K.
        • Haste M.
        • Battersby M.
        • Ilton M.
        • et al.
        Australian Indigenous chronic disease optimisation study (AUSI-CDS) prospective observational cohort study to determine if an established chronic disease health care model can be used to deliver better heart failure care among remote Indigenous Australians: Proof of concept-study rationale and protocol.
        Heart, Lung and Circulation. 2013; 22: 930-939
        • Woods J.A.
        • Katzenellenbogen J.M.
        • Davidson P.M.
        • Thompson S.C.
        Heart failure among Indigenous Australians: A systematic review.
        BMC Cardiovascular Disorders. 2012; 12: 99
        • Iyngkaran P.
        • Harris M.
        • Ilton M.
        • Kangaharan N.
        • Battersby M.
        • Stewart S.
        • et al.
        Implementing guideline based heart failure care in the Northern Territory: Challenges and solutions.
        Heart, Lung and Circulation. 2014 May; 23: 391-406
        • Iyngkaran P.
        • Tinsley J.
        • Smith D.
        • Haste M.
        • Nadarajan K.
        • Ilton M.
        • et al.
        Northern Territory Heart Failure Initiative-Clinical Audit (NTHFI-CA)-a prospective database on the quality of care and outcomes for acute decompensated heart failure admission in the Northern Territory: Study design and rationale.
        BMJ Open. 2014; 4: e004137
        • Rothwell P.M.
        Factors that can affect the external validity of randomised controlled trials.
        PLoS Clinical Trials. 2006; 1: e9
        • Rothwell P.M.
        External validity of randomised controlled trials: “To whom do the results of this trial apply?”.
        Lancet. 2005; 365: 82-93
        • MacDonald M.R.
        • Petrie M.C.
        • Hawkins N.M.
        • Petrie J.R.
        • Fisher M.
        • McKelvie R.
        • et al.
        Diabetes, left ventricular systolic dysfunction, and chronic heart failure.
        European Heart Journal. 2008; 29: 1224-1240
        • Pitt B.
        • Zannad F.
        • Remme W.J.
        • Cody R.
        • Castaigne A.
        • Perez A.
        • et al.
        The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators.
        N Engl J Med. 1999; 341: 709-717
        • Juurlink D.N.
        • Mamdani M.M.
        • Lee D.S.
        • Kopp A.
        • Austin P.C.
        • Laupacis A.
        • et al.
        Rates of hyperkalemia after publication of the randomized aldactone evaluation study.
        N Engl J Med. 2004; 351: 543-551
        • Gaglio B.
        • Shoup J.A.
        • Glasgow R.E.
        The re-aim framework: A systematic review of use over time.
        American Journal of Public Health. 2013; 103: e38-e46
        • Glasgow R.E.
        • Vogt T.M.
        • Boles S.M.
        Evaluating the public health impact of health promotion interventions: The re-aim framework.
        American Journal of Public Health. 1999; 89: 1322-1327
        • Longford N.T.
        Selection bias and treatment heterogeneity in clinical trials.
        Statistics in Medicine. 1999; 18: 1467-1474
        • Wanner C.
        • Krane V.
        • Marz W.
        • Olschewski M.
        • Mann J.F.
        • Ruf G.
        • et al.
        Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.
        N Engl J Med. 2005; 353: 238-248
        • Sun X.
        • Briel M.
        • Walter S.D.
        • Guyatt G.H.
        Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses.
        BMJ. 2010; 340: c117
        • Bakris G.L.
        • Fonseca V.
        • Katholi R.E.
        • McGill J.B.
        • Messerli F.H.
        • Phillips R.A.
        • et al.
        Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: A randomized controlled trial.
        JAMA: The Journal of the American Medical Association. 2004; 292: 2227-2236
        • Pollare T.
        • Lithell H.
        • Selinus I.
        • Berne C.
        Sensitivity to insulin during treatment with atenolol and metoprolol: A randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients.
        BMJ. 1989; 298: 1152-1157
        • Iyngkaran P.
        • Anavekar N.
        • Majoni W.
        • Thomas M.C.
        The role and management of sympathetic overactivity in cardiovascular and renal complications of diabetes.
        Diabetes & Metabolism. 2013; 39: 290-298
      1. Stumpers S, Thomson N (2013) Review of kidney disease among Indigenous people. from

        • Iyngkaran P.
        • Thomas M.
        • Majoni W.
        • Anavekar N.
        • Ronco C.
        Comorbid Heart Failure and Renal Impairment – Epidemiology and Management.
        Cardiorenal Med. 2012 Dec; 2: 281-297
        • Cohen-Solal A.
        • Kotecha D.
        • van Veldhuisen D.J.
        • Babalis D.
        • Bohm M.
        • Coats A.J.
        • et al.
        Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: Insights from the seniors trial.
        European Journal of Heart Failure. 2009; 11: 872-880
        • Krum H.
        • Iyngkaran P.
        The black dog and the weak heart: Comorbid depression in the patient with heart failure.
        Journal of Cardiac Failure. 2008; 14: 465-466
        • DiMatteo M.R.
        • Lepper H.S.
        • Croghan T.W.
        Depression is a Risk Factor for Noncompliance with Medical Treatment.
        Arch Intern Med. 2000; 160: 2101-2107
        • Tully P.J.
        • Wittert G.
        • Selkow T.
        • Baumeister H.
        The real world mental health needs of heart failure patients are not reflected by the depression randomized controlled trial evidence.
        PloS One. 2014; 9: e85928
        • Iyngkaran P.
        • Thomas M.
        • Sanders P.
        • Hare D.L.
        • Majoni W.
        • Brady S.
        • et al.
        Do we need a Wider Therapeutic Paradigm for Heart Failure with Comorbidities? - A Remote Australian Perspective.
        Health Care Current Reviews. 2013; 1: 106
        • Wong C.Y.
        • Chaudry S.I.
        • Desai M.M.
        • Krumholz H.M.
        Trends in Comorbidity, Disability, and Polypharmacy in Heart Failure.
        Am J Med. 2011; 124: 136-143
        • van der Wal M.H.L.
        • Jaarsma T.
        • van Veldhuisen D.J.
        Non-compliance in patients with heart failure; how can we manage it?.
        European Journal of Heart Failure. 2005; 7: 5-17
        • Volpe M.
        • Chin D.
        • Paneni F.
        The challenge of polypharmacy in cardiovascular medicine.
        Fundamental & Clinical Pharmacology. 2010; 24: 9-17
        • Frishman W.H.
        Importance of Medication Adherence in Cardiovascular Disease and the Value of Once-Daily Treatment Regimens.
        Cardiology in Review. 2007; 15: 257-263
        • Masoudi F.A.
        Krumholz. Polypharmacy and comorbidity in heart failure - Most patients have comorbidities that need to be addressed.
        BMJ. 2003; 327: 513-514
        • Ruf V.
        • Stewart S.
        • Pretorius S.
        • Kubheka M.
        • Lautenschlager C.
        • Presek P.
        • et al.
        Medication adherence, self-care behaviour and knowledge on heart failure in urban South Africa: The Heart of Soweto study.
        Cardiovasc J Afr. 2010; 21: 86-92
        • Corotto P.S.
        • McCarey M.M.
        • Adams S.
        • Khazanie P.
        • Whellan D.J.
        Heart Failure Patient Adherence - Epidemiology, Cause, and Treatment.
        Heart Failure Clin. 2013; 9: 49-58
        • Iyngkaran P.
        • Brown A.
        • Cass A.
        • Battersby M.
        • Nadarajan K.
        • Ilton M.
        Why it Remains Difficult for Remote Cardiologists to Obtain the Locus of Control for Ambulatory Health Care Conditions Such as Congestive Heart Failure?.
        J Gen Pract. 2014; 2: 146